Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2553459 | 0.98 | KMT2A (0.35) | CCR8KMT2A | |
| Bromide SCHEMBL15092647 | 0.98 | CCR8 (0.32) | CCR8KMT2A | |
| Hydrochloric Acid SCHEMBL15092651 | 0.98 | KMT2A (0.35) | CCR8KMT2A | |
| Trifluoroacetic Acid SCHEMBL3398634 | 0.86 | — | — | |
| SCHEMBL3829382 | 0.69 | CCR8 (0.38) | CCR8KMT2AALDH1A1 | |
| SCHEMBL8856065 | 0.65 | — | — | |
| SCHEMBL16181722 | 0.64 | — | — | |
| SCHEMBL13542070 | 0.64 | — | — | |
| SCHEMBL31748655 | 0.63 | CCR8 (0.31) | CCR8KMT2A | |
| SCHEMBL11668166 | 0.61 | MEN1 (0.31) | KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2668164-A1 | NOVEL AZACOUMARIN DERIVATIVES HAVING MDR PUMP INHIBITING ACTIVITY | Université Claude Bernard Lyon I (FR) | 2013-12-04 | — | — | EP | claimed |
| EP-2552206-A1 | TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | OncoTherapy Science, Inc. (JP) | 2013-02-06 | — | — | EP | claimed |
| WO-2012101388-A1 | NOVEL AZACOUMARIN DERIVATIVES HAVING MDR PUMP INHIBITING ACTIVITY | UNIVERSITE CLAUDE BERNARD LYON I (FR) | 2012-08-02 | — | — | WO | claimed |
| WO-2011123419-A1 | TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-10-06 | — | — | WO | claimed |
| EP-3911680-A1 | LILRB3-BINDING MOLECULES AND USES THEREFOR | University Health Network (CA) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020146946-A1 | LILRB3-BINDING MOLECULES AND USES THEREFOR | UNIVERSITY HEALTH NETWORK (CA) | 2020-07-23 | — | — | WO | disclosed |
| EP-3302060-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF -GLUCURONIDASE | Kaohsiung Medical University (TW) | 2018-04-11 | — | — | EP | disclosed |
| CN-107708419-A | Pyrazolo [4,3-c ] quinoline derivatives having inhibitory activity on bacterial glucuronidase | 高雄医学大学 | 2018-02-16 | — | — | CN | disclosed |
| WO-2016191576-A1 | PYRAZOLO[4,3-C]QUINOLINE DERIVATIVES FOR INHIBITION OF β-GLUCURONIDASE | DCB-USA LLC (US) | 2016-12-01 | — | — | WO | disclosed |
| US-8962648-B2 | Tricyclic compounds and PBK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-02-24 | — | — | US | disclosed |
| EP-2668164-A1 | NOVEL AZACOUMARIN DERIVATIVES HAVING MDR PUMP INHIBITING ACTIVITY | Université Claude Bernard Lyon I (FR) | 2013-12-04 | — | — | EP | disclosed |
| US-20130178459-A1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-07-11 | — | — | US | disclosed |
| EP-2552206-A1 | TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | OncoTherapy Science, Inc. (JP) | 2013-02-06 | — | — | EP | disclosed |
| WO-2012101388-A1 | NOVEL AZACOUMARIN DERIVATIVES HAVING MDR PUMP INHIBITING ACTIVITY | UNIVERSITE CLAUDE BERNARD LYON I (FR) | 2012-08-02 | — | — | WO | disclosed |
| WO-2011123419-A1 | TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-10-06 | — | — | WO | disclosed |
| EP-2247588-A2 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-11-10 | — | — | EP | disclosed |
| WO-2010030785-A2 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS INC. (US) | 2010-03-18 | — | — | WO | disclosed |
| WO-2009107850-A2 | FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178459-A1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | PBDC1, SBK1, PLK2 | CCR8 4149/4885KMT2A 1532/4885ALDH1A1 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.